This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase I), dose escalation and Part II (Phase II), dose expansion.
A Study of ICP-192 in Patients With Advanced Solid Tumors
-
Arizona Oncology, Tucson, Arizona, United States, 85711
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States, 92037
Rocky Mountain Cancer Centers, Aurora, Colorado, United States, 80012
Mid Florida Hematology and Oncology, Orange City, Florida, United States, 32763
Minnesota Oncology Hematology, Minneapolis, Minnesota, United States, 55404
Rutgers Cancer Institute of New Jersey, Bronx, New York, United States, 10462
Clinical Research Alliance, Lake Success, New York, United States, 11042
The Ohio State University, Columbus, Ohio, United States, 43210
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77001
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Beijing InnoCare Pharma Tech Co., Ltd.,
2024-04-15